Maxigen Biotech Inc.
1783
Rank in Stocks
#19726
Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development,... Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Formagraft, a bone graft substitute, and Formasetin, a bone void filler. For intra-articular applications in orthopedics, MBI markets injections under the names ArtiAid, ArtiAid Plus, and ArtiBest. The company's offerings also span both orthopedic and dental fields, featuring Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental graft. Specifically for dental use, MBI provides FormaAid, a collagen membrane, and the E-TECH DENTISTAR II sterilizer and disinfectant. Furthermore, HealiAid, a collagen wound dressing product, serves dental and general wound care purposes. MBI also manufactures ophthalmic viscoelastic devices, known as ViscAid, PreviscAid, and BiVisc, and produces Formaderm, a dermal filler injection utilized in plastic surgery. Beyond its medical devices, Maxigen Biotech Inc. offers a comprehensive line of skincare products. This array includes masks for the face, neck, body, and limbs, alongside make-up removers, cleansers, exfoliants, toners, essences, men's grooming items, sunscreens, and specialized body, hand, and foot care formulations. Maxigen Biotech Inc. was established in 1998 and operates from its main office in Taoyuan City, Taiwan.
Share Price
$1.09
Last synced: 2026-11-13
Market Cap
$98.01M
Change (1 day)
0.36%
Change (1 year)
-23.32%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Maxigen Biotech Inc. (1783)
Category
Healthcare
EPS for Maxigen Biotech Inc. (1783)
EPS as of September 2026 TTM: $0.12
According to Maxigen Biotech Inc.'s latest financial reports, its current EPS (TTM) is $0.12. At the end of 2025 the company had an EPS of $0.09, an increase over its 2024 EPS of $0.06.
EPS history for Maxigen Biotech Inc. from 2009 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.12 | 34.11% |
| 2025 | $0.09 | 45.30% |
| 2024 | $0.06 | 7.10% |
| 2023 | $0.06 | 18.36% |
| 2022 | $0.05 | 35.09% |
| 2021 | $0.04 | 34.88% |
| 2020 | $0.03 | 11.95% |
| 2019 | $0.03 | 14.61% |
| 2018 | $0.02 | 208.45% |
| 2017 | $0.01 | -244.90% |
| 2016 | 0.00 | -80.08% |
| 2015 | $-0.02 | 211.39% |
| 2014 | $-0.01 | -758.33% |
| 2013 | 0.00 | -25.00% |
| 2012 | 0.00 | -107.44% |
| 2011 | $-0.02 | 115.00% |
| 2010 | $-0.01 | -213.64% |
| 2009 | $0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $8.37 | 6,834.55% |
US
|
|
| $5.95 | 4,831.81% |
FR
|
|
| $4.15 | 3,338.28% |
US
|
|
| $5.26 | 4,257.42% |
JP
|
|
| $1.34 | 1,010.19% |
CH
|
Questions about Maxigen Biotech Inc.'s earnings per share (EPS)
What is Maxigen Biotech Inc.'s earnings per share (EPS)?
Maxigen Biotech Inc.'s earnings per share (EPS) over the last twelve months is $0.12, as of Sep 2026.
What was Maxigen Biotech Inc.'s earnings per share (EPS) in 2025?
In 2025, Maxigen Biotech Inc.'s earnings per share (EPS) was $0.09, 50.00% more than in 2024 ($0.06).
How has Maxigen Biotech Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Maxigen Biotech Inc.'s earnings per share (EPS) went from $0.03 to $0.09, an average growth of 24.57% a year.
How does Maxigen Biotech Inc.'s earnings per share (EPS) compare with similar companies?
Maxigen Biotech Inc.'s earnings per share (EPS) ($0.12) is lower than that of all 5 similar companies listed above. The highest among them is Intuitive Surgical, Inc., with $8.37.